In colorectal and pancreatic cancer surgery, the intraoperative use of a fluorochrome-labeled anti-CEA monoclonal antibody, SGM-101, provides an enhanced differentiation between tumor and normal tissue [19]. Here, CEACAM5 is linked to pancreatic neoplasm.